R Squared’s scPharmaceuticals SCPH Stock Holding History

R Squared’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,492	Closed	-$12.4K	–	1279
2024 Q4	$12.4K	Buy	+3,492	New	+$13.4K	0.01%	1080

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

R Squared's SCPH Position: Q1 2025 in Review

R Squared sold out of scPharmaceuticals (SCPH) in Q1 2025, closing a stake of 3,492 shares — an estimated $12.4K sold.

R Squared first reported a position in SCPH in Q4 2024 and held it in 1 quarter. The position peaked at $12.4K in Q4 2024. 88 funds tracked by Wall St. Rank hold SCPH as of Q1 2025.

R Squared reported no remaining scPharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 3,492 scPharmaceuticals shares in Q1 2025, an estimated $12.4K.
R Squared first reported a position in scPharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's scPharmaceuticals position peaked at $12.4K in Q4 2024.
88 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.